Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to current ...
Jan. 22, 2026 Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of the disease. An experimental antibody targets a protein that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results